Bengbu Medical College   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bengbu City China (1958)

Organization Overview

First Clinical Trial
2010
NCT01172002
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bengbu Medical College | Bengbu Medical College Affiliated Hospital | Bengbu Medical College First Hospital | First Affiliated Hospital Bengbu Medical College | First Affiliated Hospital of Bengbu Medical College | Lianyungang Hospital Affiliated Bengbu Medical College | The First Affliated Hospital of Bengbu Medical College | Yan Yang, MD, Ph.D

Active Ingredients

Drugs in Phase 4 Trials (5)

carrimycin (1 trial)

chloroquine (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

lopinavir (Kaletra) (1 trial)

ritonavir (Norvir) (1 trial)

Drugs in Phase 3 Trials (6)

ciltacabtagene autoleucel (Carvykti) (1 trial)

clarithromycin (biaxin) (1 trial)

dexamethasone (2 trials)

Epimedium (1 trial)

lenalidomide (revlimid) (1 trial)

sorafenib (nexavar) (1 trial)

Drugs in Phase 2 Trials (15)

autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)

autologous hematopoietic stem cells (1 trial)

azacitidine (vidaza) (4 trials)

bevacizumab (avastin) (2 trials)

chidamide (1 trial)

cladribine (leustatin) (2 trials)

cytarabine (cytosar-u) (2 trials)

duloxetine (Cymbalta) (1 trial)

inotuzumab ozogamicin (besponsa) (1 trial)

irinotecan (Camptosar) (1 trial)

lapatinib (tykerb) (4 trials)

paclitaxel (taxol) (1 trial)

tgrx-326 (1 trial)

ulinastatin (1 trial)

venetoclax (venclexta) (6 trials)

Drugs in Phase 1 Trials (15)

anfibatide (1 trial)

diphenhydramine (benadryl) (1 trial)

hb0017 (1 trial)

hb0030 (1 trial)

interferon alpha-1 (1 trial)

methylprednisolone (medrol) (1 trial)

neoantigen dna vaccine (1 trial)

nggt002 (1 trial)

nivolumab (opdivo) (1 trial)

pegloticase (krystexxa) (1 trial)

rt-01 (3 trials)

sars-cov-2 mrna vaccine, bivalent (2 trials)

sph 3348 (1 trial)

Telitacicept (1 trial)

tr64 (1 trial)

Drugs in Other Trials (11)

azathioprine (imuran) (1 trial)

bivalent bnt162b2 (Comirnaty) (1 trial)

covid-19 variant (omicron ba.5) mrna vaccine (1 trial)

dexmedetomidine (precedex) (1 trial)

inactivated covid-19 vaccine (1 trial)

leflunomide (arava) (1 trial)

midazolam (versed) (1 trial)

norepinephrine (levophed) (1 trial)

omicron covid-19 vaccine (vero cell), inactivated (1 trial)

sars-cov-2 variant (omicron ba.5) mrna vaccine (3 trials)

terlipressin (Terlivaz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Ascites (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Communicable Diseases (Phase 4)

Coronavirus Infections (Phase 4)

Glioma (Phase 2)

Infections (Phase 4)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial APIs: 52